Announcements Trials
Browse Landscape

Phase

Phase 2 6

Status

Unknown 6

Sponsor Class

OTHER 4UNKNOWN 2

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 6

Conditions

Neoplasm Metastasis 6Lymphoma, Extranodal NK-T-Cell 6Carcinoma, Hepatocellular 5Stomach Neoplasms 3Nasopharyngeal Carcinoma 3Locally Advanced Rectal Cancer 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumor 3Triple Negative Breast Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Nasopharyngeal Neoplasms 2Melanoma 2Epstein-Barr Virus Infections 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Pancreatic Adenocarcinoma Metastatic 1Osteosarcoma 1Objective Response Rate 1NSCLC 1Muscle-Invasive Bladder Carcinoma 1Lymphoma, T-Cell 1Lymphoma 1Kidney Neoplasms 1Immunoblastic Lymphadenopathy 1

Interventions

pegaspargase 14Etoposide 11Dexamethasone 11Gemcitabine 10spartalizumab 6Oxaliplatin 4sintilimab 3Radiotherapy 3N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 3Methotrexate 3Asparaginase 3tislelizumab 2camrelizumab 2Lenalidomide 2Drug Therapy 2Cyclophosphamide 2Cisplatin 2Busulfan 2Azacitidine 2toripalimab 1tofacitinib 1ruxolitinib 1romidepsin 1pembrolizumab 1fludarabine phosphate 1avelumab 1apatinib 1Thalidomide 1Sensitivity and Specificity 1Psychiatric Rehabilitation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Extranodal NK-T-Cell × spartalizumab × Clear all
NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

ChineseAMS

Phase 2 Unknown
54 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT05149170 2021-12-08

Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL

ChineseAMS

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04676789 2020-12-21

SPENT

Sun Yat-sen University

Phase 2 Unknown
30 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04279379 2020-05-07

Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

Beijing Tongren Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04338282 2020-04-08

Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma

Beijing Tongren Hospital

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

NCT04096690 2020-03-11

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

Ruijin Hospital

Phase 2 Unknown
22 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡